M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs BioSpaceSupernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost...NeuroscienceRead full story pharminent August 3, 2026 (Last updated: August 6, 2026) BioSpace Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost… Neuroscience Read full story Post navigation Previous: Curium strikes $8bn deal to buy radiopharma rival LantheusNext: AstraZeneca and Bristol Myers Squibb Reported to Have Held Mega-Merger Talks Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026